Success Metrics

Clinical Success Rate

100.0%

Based on 6 completed trials

Completion Rate

100%(6/6)

Active Trials

0(0%)

Results Posted

0%(0 trials)

Phase Distribution

Ph phase_1

17%

Ph phase_3

17%

Ph phase_4

33%

Phase Distribution

Early Stage

Mid Stage

Late Stage

Phase Distribution4 total trials

Phase 1Safety & dosage

1(25.0%)

Phase 3Large-scale testing

1(25.0%)

Phase 4Post-market surveillance

2(50.0%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

100.0%

6 of 6 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

trials recruiting

Total Trials

all time

Status Distribution

Completed(6)

Detailed Status

Completed6

Development Timeline

Analytics

Development Status

Total Trials

Active

Success Rate

100.0%

Most Advanced

Phase 4

Trials by Phase

Phase 11 (25.0%)

Phase 31 (25.0%)

Phase 42 (50.0%)

Trials by Status

completed6100%

Recent Activity

0 active trials

Showing 5 of 6

completedphase_4

Safety and Effectiveness of Opicapone Plus Standard of Care in Elderly Patients With Parkinson's Disease

NCT03959540

completedphase_3

Continuation Treatment Protocol for Patient Who Participated in the BIA 9-1067-302 Clinical Trial

NCT01851850

View all 6 trials

Clinical Trials (6)

Showing 6 of 6 trials

NCT04990284Phase 4

eArly levoDopa With Opicapone in Parkinson's paTients wIth motOr fluctuatioNs.

Completed

NCT04986995Phase 4

OpicApone Sleep dISorder

Completed

NCT04787965

Opicapone Treatment Initiation Open-Label Study

Completed

NCT03959540

Safety and Effectiveness of Opicapone Plus Standard of Care in Elderly Patients With Parkinson's Disease

Completed

NCT01851850Phase 3

Continuation Treatment Protocol for Patient Who Participated in the BIA 9-1067-302 Clinical Trial

Completed

NCT03496870Phase 1

A Study of the Pharmacokinetics, Pharmacodynamics, and Safety of Opicapone in Subjects With Parkinson's Disease Taking Levodopa.

Completed

All 6 trials loaded

Drug Details

Intervention Type: DRUG
Total Trials: 6